Basic Etoricoxib Information

• INN (International Nonproprietary Name): Etoricoxib
• Brand Names Available In United Kingdom: Arcoxia, Etoricoxib Accord
• ATC Code: M01AH05
• Forms & Dosages: Oral film-coated tablets commonly 30 mg (rare), 60 mg, 90 mg, 120 mg; no injectable or topical forms registered
• Manufacturers In United Kingdom: Merck Sharp & Dohme (MSD), Accord, Milpharm
• Registration Status In United Kingdom: Approved; Prescription Only Medicine (POM)
• OTC / Rx Classification: Prescription Only Medicine (POM)

Key Findings From Recent Trials

Major 2022–2025 Studies

What does the recent evidence actually say about etoricoxib for pain control?

High‑quality randomised controlled trials and pooled meta‑analyses from 2022–2024 consistently evaluated etoricoxib against non‑selective NSAIDs and other COX‑2 inhibitors.

Indications studied included osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gout, with additional trials for acute dental pain and post‑operative analgesia.

Study designs typically used once‑daily etoricoxib at doses matching product information (30–120 mg) and excluded patients with established ischaemic heart disease or heart failure.

Main Outcomes

Does etoricoxib work as well as other NSAIDs?

Across trials the analgesic effect of etoricoxib is comparable to other NSAIDs and COX‑2 inhibitors for chronic musculoskeletal conditions.

For osteoarthritis and ankylosing spondylitis, efficacy signals are strongest at 60–90 mg once daily with measurable reduction in pain intensity and improvements in function scores.

Short courses at 120 mg produced clear benefit for acute gout, with trials limiting treatment to the recommended maximum of eight days.

In acute dental pain, etoricoxib showed a faster onset of relief versus some non‑selective NSAIDs in randomised comparisons, often used at 90 mg for up to three days.

Safety Observations

What safety issues did recent trials highlight?

Recurrent safety signals relate to dose‑dependent increases in blood pressure and peripheral oedema, and occasional transient liver‑enzyme elevations.

Serious gastrointestinal bleeding and peptic ulceration occurred less frequently than with non‑selective NSAIDs in pooled analyses.

Comparative meta‑analyses suggest a trend towards increased cardiovascular events in patients with existing cardiovascular risk factors, consistent with underlying COX‑2 pharmacology.

Generalisability is limited because many trials excluded people with established ischaemic heart disease, heart failure or uncontrolled hypertension.

Clinical Mechanism Of Action

Layman’s Explanation

How does etoricoxib reduce pain in plain terms?

Etoricoxib blocks COX‑2 enzymes that make prostaglandins which cause pain and inflammation.

By targeting COX‑2 more selectively than older NSAIDs, etoricoxib reduces pain and swelling with less irritation to the stomach lining for many patients.

Scientific Breakdown

What is happening at the molecular level?

Etoricoxib is a highly selective COX‑2 inhibitor (ATC M01AH05) that binds preferentially to COX‑2 versus COX‑1 enzymes.

Selective COX‑2 inhibition reduces gastric mucosal prostaglandin suppression and underpins a lower rate of upper GI ulcers compared with non‑selective NSAIDs.

However, blocking COX‑2 shifts the prostanoid balance by reducing prostacyclin without affecting thromboxane A2, which can increase pro‑thrombotic tendency and cardiovascular risk in susceptible patients.

Pharmacokinetics support once‑daily oral dosing with marketed tablets of 30, 60, 90 and 120 mg, and hepatic metabolism requires dose adjustments in liver impairment.

Renal function must be considered because NSAID effects on renal perfusion can worsen kidney function; avoid in severe renal impairment (eGFR <30 mL/min).

Scope Of Approved And Off‑Label Use

United Kingdom Approvals

What is etoricoxib approved for in the UK?

In the United Kingdom etoricoxib is a Prescription Only Medicine and product information covers osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, chronic low back pain, acute gout and acute dental pain.

Typical approved doses range from 30 mg to 120 mg once daily depending on indication and duration.

Prescribers must follow the Summary of Product Characteristics and local formulary requirements when initiating treatment.

Notable Off‑Label Trends

When do clinicians sometimes use etoricoxib beyond labelled indications?

Where non‑selective NSAIDs are poorly tolerated because of GI history, clinicians may prescribe etoricoxib for refractory musculoskeletal pain syndromes as a considered off‑label option.

Primary care and secondary clinicians sometimes use short courses for post‑operative or acute musculoskeletal flares, mindful of cardiovascular contraindications and renal status.

Prescribing patterns vary internationally because etoricoxib is not FDA‑approved in the United States, which influences clinician familiarity and availability of generics.

Dosage Strategy

General Dosing

What is the basic principle for dosing?

Use the lowest effective dose for the shortest required duration to balance analgesia and safety.

Standard oral formulations include 30 mg (rare), 60 mg, 90 mg and 120 mg with once‑daily dosing the routine approach.

Condition‑Specific Dosing

Which dose for which condition?

• Osteoarthritis: 30–60 mg once daily; prefer lower end for long‑term management and review periodically.
• Rheumatoid Arthritis: 60–90 mg once daily, titrate by response and tolerability.
• Ankylosing Spondylitis: commonly 90 mg once daily for symptom control.
• Acute Gout: 120 mg once daily for up to eight days (maximum recommended).
• Acute Dental Pain: 90 mg once daily for short term use, typically up to three days.

Adjustments: avoid in severe renal impairment (eGFR <30 mL/min), and follow hepatic dosing rules—mild impairment maximum 60 mg/day, moderate impairment 60 mg every other day, severe impairment contraindicated.

Elderly patients do not require routine dose reduction but need close monitoring of renal function, blood pressure and liver tests when on chronic therapy.

Safety Protocols

Contraindications

Who must not take etoricoxib?

Absolute contraindications include known hypersensitivity to etoricoxib or other coxibs, active peptic ulcer or gastrointestinal bleeding, severe hepatic or renal impairment, heart failure, uncontrolled hypertension, established ischaemic heart disease, peripheral arterial disease and cerebrovascular disease.

Avoid use in pregnancy and breastfeeding unless the potential benefit outweighs risk, and do not use in late pregnancy.

Adverse Effects

What side effects should patients expect and how to monitor?

Common adverse effects include headache, dizziness, peripheral oedema, hypertension, dyspepsia, nausea and transient increases in liver enzymes.

Serious but less frequent events include gastrointestinal bleeding, ulceration and cardiovascular events such as myocardial infarction and stroke, particularly in patients with cardiovascular risk factors.

Baseline assessment should include blood pressure, renal function and liver enzymes, and periodic monitoring is recommended for chronic use—typically every 3–6 months or sooner if new risk factors emerge.

For acute indications such as gout or dental pain, use the recommended short durations to limit cumulative risk and reassess if symptoms persist beyond the treatment window.

Interaction Mapping

Food Interactions

Are there foods to avoid?

No major food interactions require avoidance, although taking the tablet with food can reduce gastric discomfort for some patients.

Counsel patients to minimise alcohol consumption while taking etoricoxib because of additive gastrointestinal and hepatic risks.

Drug Combinations To Avoid

Which medicines require care or avoidance?

• Avoid combining etoricoxib with other NSAIDs or regular aspirin because of additive gastrointestinal and cardiovascular risks.
• Anticoagulants and antiplatelets (warfarin, DOACs, aspirin, clopidogrel) raise bleeding risk; monitor INR and bleeding signs closely if combined.
• ACE inhibitors, ARBs and diuretics can have reduced renoprotective effect with NSAIDs and risk acute kidney injury—beware the "triple whammy" when diuretic + ACEi + NSAID are used together.
• Monitor lithium and methotrexate levels when combined with NSAIDs due to reduced renal clearance and potential toxicity.
• SSRIs may increase bleeding risk when used with NSAIDs; counsel patients accordingly.
• Etoricoxib is metabolised hepatically; check for strong CYP inhibitors or inducers and monitor when relevant co‑medications are present.

Patient Experience Analysis

Survey Data

What do patients report in trials and surveys?

Patient‑reported outcomes in clinical trials and observational cohorts show good short‑term pain relief and improved function in OA, RA and AS with etoricoxib, often citing once‑daily dosing convenience.

Primary care surveys frequently report higher satisfaction where patients experienced better gastrointestinal tolerance compared with prior non‑selective NSAIDs.

Adherence improvements are commonly linked to the simplicity of once‑daily dosing compared with multiple daily NSAID regimens.

Forum Trends

What do social posts and forums say?

Qualitative social‑listening themes include reports of effective pain control at 60–90 mg, quick relief for dental pain, and concerns about swelling or weight gain from peripheral oedema.

Many patients are aware of cardiovascular warnings and some report switching back to non‑selective NSAIDs for cost or prescriber preference reasons.

Clinicians note improved adherence but emphasise careful screening for cardiovascular and renal risk before prescribing.

Remember that forum data is anecdotal and should not replace trial evidence or regulatory guidance when making prescribing decisions.

Distribution And Pricing Landscape

Availability And Brands

Where is etoricoxib sold and in what forms?

Etoricoxib is marketed in the UK under brand names such as Arcoxia and generics like Etoricoxib Accord, commonly in blister packs of 28 tablets and available in 60 mg, 90 mg and 120 mg strengths.

Manufacturers supplying the UK market include MSD, Accord and Milpharm, while other European generics come from Zentiva, Teva, Sandoz, Ratiopharm and others.

Pricing And Access

How is etoricoxib priced and accessed?

As a Prescription Only Medicine in the UK, NHS prescribing depends on local formularies and cost‑effectiveness compared with alternatives, while private prescription prices vary by brand and pack size.

Generics tend to reduce cost and improve availability in community and e‑pharmacies.

In our online pharmacy, etoricoxib is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Alternative Options

Comparison Table

How does etoricoxib compare with other analgesic choices?

Etoricoxib is a COX‑2 selective inhibitor offering effective analgesia, lower upper GI ulcer risk versus non‑selective NSAIDs and once‑daily dosing from 30–120 mg.

Celecoxib is an alternative COX‑2 inhibitor available in the UK with similar GI benefits and cardiovascular caveats.

Naproxen and ibuprofen are non‑selective NSAIDs with proven analgesic effect; naproxen has some data suggesting a lower cardiovascular signal but carries higher GI risk and often requires multiple daily doses.

Parecoxib offers a parenteral COX‑2 option for short‑term surgical analgesia but is of limited ambulatory use.

Pros And Cons

• Etoricoxib — Pros: effective pain relief, reduced upper GI risk versus non‑selective NSAIDs, once‑daily dosing. Cons: increased cardiovascular risk in high‑risk patients, contraindicated in heart failure, not FDA‑approved.
• Celecoxib — Pros: established COX‑2 option in UK, lower GI risk versus NSAIDs. Cons: similar cardiovascular considerations, dose‑dependent effects.
• Naproxen — Pros: effective, some data supporting lower CV signal. Cons: higher GI risk and multiple daily dosing.
• Ibuprofen — Pros: widely available and inexpensive. Cons: GI and renal risks at higher doses.

Choose by weighing cardiovascular and gastrointestinal risk, renal and hepatic function, dosing convenience and cost, and use shared decision‑making with the patient.

Regulatory Status

Where is etoricoxib approved and what are the regulatory considerations?

Etoricoxib is approved across the EU with EMA product information and in the UK via the MHRA as a Prescription Only Medicine.

The drug is registered by national agencies such as TGA in Australia and Health Canada, and it is available in over 60 countries.

It is not approved by the US FDA, which affects availability and international prescribing patterns.

Regulatory SPCs specify contraindications including heart failure and severe hepatic or renal impairment, dose limits in hepatic disease and duration limits for acute gout (maximum eight days).

Pharmacovigilance recommendations include monitoring blood pressure, liver enzymes and renal function during therapy.

Consolidated FAQ

Quick Answers For Clinicians & Patients

What is the first‑line indication?

Symptomatic relief in osteoarthritis is the common starting indication, with product information also covering RA, ankylosing spondylitis, acute gout and acute dental pain.

Is it available over the counter in the UK?

No; etoricoxib is a Prescription Only Medicine in the United Kingdom.

Can I take it with aspirin?

Avoid routine combination with aspirin because of additive bleeding and cardiovascular risks; consult the prescriber for specific clinical contexts.

How long can I take 120 mg?

120 mg is indicated for acute gout only and should be used for a maximum of eight days as per the product information.

What monitoring is needed?

Baseline and periodic monitoring should include blood pressure, renal function (creatinine/eGFR) and liver enzymes for chronic use.

Is it safe in pregnancy or breastfeeding?

Generally avoid; etoricoxib is contraindicated in late pregnancy and should be used only if the potential benefit justifies risk in breastfeeding—discuss alternatives.

Can patients switch from other NSAIDs?

Yes, but assess cardiovascular, gastrointestinal and renal risk and avoid NSAID duplication when switching.

Visual Guide

What figures help explain etoricoxib quickly?

Recommended visuals include a COX‑1 versus COX‑2 pathway diagram showing prostacyclin and thromboxane balance, an infographic mapping 30/60/90/120 mg tablets to indications and durations, a risk stratification flowchart for pre‑prescription checks and monitoring, and a packaging gallery showing Arcoxia and common generics in UK pack sizes.

Use vector diagrams for the mechanism and PNG for infographics, include accessible alt text and reference the EMA/MHRA SPC on each visual.

Storage And Transport

How should etoricoxib be stored and shipped?

Store tablets below 30°C, protected from moisture and light, and do not refrigerate.

Transport in original packaging to preserve blister integrity and avoid exposure to high humidity.

Pharmacies should check batch and expiry dates on blister packs and follow NHS disposal procedures for expired stock.

Advise patients to keep tablets at room temperature, away from bathrooms and direct sunlight, and out of reach of children.

Guidelines For Proper Use

Prescribing Checklist

What should a prescriber confirm before issuing etoricoxib?

Confirm the indication is consistent with the SPC, and review cardiovascular history including ischaemic heart disease, stroke and heart failure.

Assess gastrointestinal history for ulcers or bleeding and check baseline renal and liver function tests.

Document baseline blood pressure, creatinine/eGFR and liver enzymes in the patient record before starting chronic therapy.

Choose the lowest effective dose and avoid use in severe hepatic or renal impairment.

For patients with significant cardiovascular risk consider alternatives or seek secondary care input.

Follow‑Up & Discontinuation

How should patients be followed up and when should the drug be stopped?

Schedule periodic reviews for chronic therapy every three to six months including blood pressure, renal and liver tests, and reassess analgesic benefit and functional improvement.

Attempt dose reduction or drug holiday when possible to limit cumulative risk.

For acute indications adhere to recommended maximum durations—gout up to eight days, dental pain up to three days—and reassess if symptoms persist.

If a patient develops new hypertension, peripheral oedema, significant liver‑enzyme elevation or any sign of gastrointestinal bleeding, stop etoricoxib and arrange urgent review.

Delivery Across United Kingdom

Practical Prescribing Scenarios

How does this look in day‑to‑day practice?

Scenario: a 68‑year‑old patient with symptomatic osteoarthritis controlled insufficiently on paracetamol and intolerant of ibuprofen because of gastric upset.

Consider starting etoricoxib 30–60 mg once daily after documenting baseline BP, renal and liver tests and confirming no history of heart failure or ischaemic heart disease.

Arrange review in 6–12 weeks to assess pain, function and tolerability and repeat blood pressure and basic labs as needed.

Scenario: a patient with an acute gout flare who is not a candidate for colchicine or NSAID alternatives.

Short course etoricoxib 120 mg once daily for up to eight days can be prescribed, with a plan for review and escalation if no improvement.

Final Notes For Clinicians

What are the takeaways when choosing etoricoxib?

Etoricoxib is a useful once‑daily COX‑2 selective option for patients needing effective analgesia where stomach tolerance or dosing convenience is important.

Always screen for cardiovascular, renal and hepatic contraindications, document baseline tests and monitor during chronic use.

Discuss risks and benefits with patients and record shared decision‑making in the clinical record.

For patients seeking information, provide clear guidance on dosing, monitoring and when to stop treatment and seek help.